Dr. Weisman participates in FDA Advisory Committee
The committee convened to discuss tofersen, an experimental injection for treatment of ALS.
dcw
ANA administers first lecanemab infusion in PA
Leqembi significantly reduces progression of memory loss in those with Alzheimer’s disease by about 30%.
Dr. Weisman Quoted in Philadelphia Inquirer Article on Lecanemab
Blood tests for Alzheimer’s biomarkers will be a powerful tool in determining who will benefit from a drug.
Dr. Weisman Quoted in NY Times Article on Aducanumab
Medicare should require safety monitoring and medical expertise in the use of aducanumab.
Aducanumab: Neither Far Nor Deep
While we might not have clear progress, we do have an advance.
Alzheimer’s Disease: Mystery No More
It was once so common to be forgetful in old age that it was thought to be normal. But normal aging only includes things like tip-of-tongue memory loss and forgetting faces.
Dr. Weisman interviewed on Senior Advocates, Who’s Who
Dr. Weisman discusses COVID-19, Alzheimer’s disease, and clinical research with Jerry Rothkoff.
Dr. Weisman interviewed in Neurology Insights
Dr. Weisman has been interviewed in a new article in Neurology Insights regarding the unique challenges faced by Alzheimer’s patients and caregivers during the pandemic.
The Pandemic Will End: How and Why
In many ways we’ve been fortunate. Despite a pandemic, society has not broken down.
Alzheimer’s Patient Newsletter February 2020
Aducanumab, the first Alzheimer’s-modifying therapy, submitted to the FDA. Can Biogen recover from their errors?